Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

IMMUNOTHERAPY

Translating noninvasive molecular responses into clinical reality for cancer immunotherapy

Nature Reviews Clinical Oncology volume 18, pages 65–66 (2021)Cite this article

Subjects

Noninvasive liquid biopsy assays integrating tumour and immune biomarkers are a promising tool to enhance clinical decision-making in immuno-oncology. Here, we discuss how circulating tumour DNA dynamics, in conjunction with pre-treatment tumour and immune features, can predict clinical response to immune-checkpoint inhibitors alongside the challenges in making their use a clinical reality.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Integrative on-treatment molecular response prediction can guide adaptive immuno-oncology clinical trials.

References

  1. Anagnostou, V. et al. Dynamics of tumor and immune responses during immune checkpoint blockade in non-small cell lung cancer. Cancer Res. 79, 1214–1225 (2018).

    Article  Google Scholar 

  2. Bratman, S. V. et al. Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. Nat. Cancer 1, 873–881 (2020).

    Article  Google Scholar 

  3. Zhang, Q. et al. Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade. Cancer Discov. CD-20-0047 (2020).

  4. Anagnostou, V. et al. Evolution of neoantigen landscape during immune checkpoint blockade in non–small cell lung cancer. Cancer Discov. 7, 264–276 (2017).

    Article  CAS  Google Scholar 

  5. Yost, K. E. et al. Clonal replacement of tumor-specific T cells following PD-1 blockade. Nat. Med. 25, 1251–1259 (2019).

    Article  CAS  Google Scholar 

  6. Nabet, B. Y. et al. Noninvasive early identification of therapeutic benefit from immune checkpoint inhibition. Cell 183, 363–376 (2020).

    Article  CAS  Google Scholar 

  7. Kurtz, D. M. et al. Dynamic risk profiling using serial tumor biomarkers for personalized outcome prediction. Cell 178, 699–713 (2019).

    Article  CAS  Google Scholar 

  8. Reuben, A. et al. Comprehensive T cell repertoire characterization of non-small cell lung cancer. Nat. Commun. 11, 603 (2020).

    Article  CAS  Google Scholar 

  9. Zhang, J. et al. Compartmental analysis of T-cell clonal dynamics as a function of pathologic response to neoadjuvant PD-1 blockade in resectable non–small cell lung cancer. Clin. Cancer Res. 26, 1327–1337 (2020).

    Article  CAS  Google Scholar 

  10. Cristiano, S. et al. Genome-wide cell-free DNA fragmentation in patients with cancer. Nature 570, 385–389 (2019).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The work of the authors is supported in part by the US National Institutes of Health grant CA121113 (V.A.), the Bloomberg-Kimmel Institute for Cancer Immunotherapy (J.C.M. and V.A.), the V Foundation (V.A.), the LUNGevity Foundation (V.A.), the Emerson Collective Cancer Research Fund (V.A.), the Conquer Cancer Foundation Young Investigators Award (J.C.M.), and the US National Cancer Institute T32 training grant CA009071 (J.C.M.).

Author information

Authors and Affiliations

  1. The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA

    Joseph C. Murray & Valsamo Anagnostou

  2. The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD, USA

    Joseph C. Murray & Valsamo Anagnostou

Authors
  1. Joseph C. Murray
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Valsamo Anagnostou
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Valsamo Anagnostou.

Ethics declarations

Competing interests

V.A. receives research funding from Bristol–Myers Squibb. J.C.M. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Murray, J.C., Anagnostou, V. Translating noninvasive molecular responses into clinical reality for cancer immunotherapy. Nat Rev Clin Oncol 18, 65–66 (2021). https://doi.org/10.1038/s41571-020-00450-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41571-020-00450-4

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer